Next Generation Sequencing (NGS) - Principles, Workflow, and Applications
Foundations of Next Generation Sequencing and Clinical Genetics
Definition and core identity of Next Generation Sequencing (NGS):
High-throughput DNA sequencing technology that enables the simultaneous sequencing of millions of DNA fragments.
Also termed massively parallel sequencing due to its capacity to execute millions of independent sequencing reactions in parallel.
Substantially increases data output while reducing the turnaround time and cost per base compared to first-generation Sanger sequencing.
Role of NGS in clinical genetics and Neuromuscular Disorders (NMDs):
Primary clinical utility lies in identifying pathogenic mutations responsible for inherited disorders.
Neuromuscular disorders serve as a primary clinical model: a heterogeneous group of conditions impairing the nerves and muscles responsible for movement.
Population prevalence: approximately individuals.
Clinical severity: ranges from mild functional impairment to devastating, life-threatening disability.
Age of onset: spans from fetal development through late adulthood.
Healthcare burden: exerts profound impacts on affected individuals, family networks, and public healthcare infrastructures.
Diagnostic challenge: high genetic complexity where hundreds of distinct disorders manifest with virtually indistinguishable, overlapping clinical presentations.
Monogenic diseases and diagnostic complexity:
Monogenic disease definition: a genetic pathology caused by a disease-associated variant situated within a single gene.
The presence of hundreds of distinct neuromuscular conditions with overlapping clinical features complicates phenotypic differentiation, making genetic sequencing essential to isolate the precise causative gene.
Clinical necessity of establishing a genetic diagnosis:
Patients presenting with identical clinical phenotypes frequently have completely different:
Underlying genetic causes.
Medical management and therapeutic interventions.
Disease prognoses and progression timelines.
Modes of inheritance and recurrence risks for biological relatives.
Diagnostic benefits:
Provides clinical certainty and diagnostic resolution.
Terminates lengthy "diagnostic odysseys" that often subject patients to years of invasive, inconclusive investigations.
Directly guides personalized treatment regimens and clinical management.
Informs family planning and reproductive risk assessments.
Eliminates the necessity for further invasive clinical procedures (e.g., muscle biopsies).
Pedigree analysis in familial disease investigation:
Exemplified by a Tasmanian family pedigree affected by a genetic neuromuscular condition.
Standard pedigree nomenclature:
Filled circle: Affected female.
Unfilled circle: Unaffected female.
Filled square: Affected male.
Unfilled square: Unaffected male.
Observational utility: demonstrates phenotypic transmission across multiple generations and establishes that both sexes are affected, illustrating how family histories guide targeted molecular analysis.
Historical Evolution and Applications of Genomic Sequencing
Limitations of traditional sequencing methodologies:
Prior to high-throughput platforms, economic and throughput constraints restricted researchers to sequencing approximately candidate genes per subject.
Candidate gene selection relied on clinical predictions; this strategy frequently failed due to extensive phenotypic overlap across genetically distinct disorders.
NGS bypassed candidate gene limitations by enabling hypothesis-free, multi-gene or genome-wide investigation.
The Human Genome Project (HGP):
Coordinated international biological initiative spanning from .
Objective: comprehensively determine the nucleotide sequence of the human genome.
Established the foundational reference sequence required for the emergence of modern genomics and the implementation of high-throughput sequencing pipelines.
Economic trajectory of DNA sequencing:
Historical sequencing expenditure demonstrated a steep reduction in the cost required to sequence a human genome, particularly from .
The operational implementation of NGS drove this hyper-accelerated cost reduction below conventional trajectories, democratizing genomic analysis for clinical diagnostics and academic research.
Major biological and clinical applications of NGS:
Molecular biology: elucidating novel genes, mapping structural variants, and characterizing downstream molecular pathways.
Evolutionary biology: conducting inter-species comparative genomics to trace phylogenetic lineage and evolutionary divergence.
Metagenomics: directly profiling collective genomic material recovered from diverse polymicrobial communities.
Cancer oncology: cataloging somatic mutations, chromosomal rearangements, and copy-number changes driving tumourigenesis.
RNA expression profiling (RNA-Seq): quantifying whole-transcriptome gene expression levels and alternative splicing dynamics.
Epigenetic sequencing: mapping chromatin modifications, histone alterations, and DNA methylation patterns involved in transcriptional regulation.
Comparative Modalities of Next Generation Sequencing
Whole Genome Sequencing (WGS):
Scope: sequences the complete genome, including all protein-coding exons and non-coding intronic and intergenic spaces.
Advantages:
Comprehensive genomic coverage.
Capable of identifying all classes of structural, coding, and regulatory variation.
Captures critical regions excluded from exome or targeted panel capture kits.
Limitations:
Generates immense datasets requiring specialized bioinformatic storage and compute infrastructure.
Interpreting the pathological significance of non-coding variants remains exceptionally difficult.
Strategic standing: represents the definitive future direction of clinical genomics.
Whole Exome Sequencing (WES):
Scope: selectively targets and sequences the protein-coding exons of the genome.
Genomic metrics:
The exome accounts for approximately of the total human genome.
Approximately of currently cataloged Mendelian disease-causing variants reside within these protein-coding sequences.
Advantages:
Concentrates sequencing depth on genomic loci with the highest probability of harboring high-impact variants.
Substantially reduced data footprint relative to WGS.
Cost-effective workhorse for novel disease-gene discovery.
Limitations:
Completely excludes the vast majority of non-coding regulatory elements.
Fails to capture structural or nucleotide variants that fall outside the targeted exonic boundaries.
Strategic standing: primary mainstay for current clinical and academic genetic research.
Targeted Gene Panels:
Scope: exclusively sequences a pre-curated subset of genes clinically implicated in specific phenotypic disorders.
Clinical archetypes:
Somatic tumour profiling panels.
Inherited retinal and eye disease panels.
Familial cardiovascular disease panels.
Advantages:
Maximum clinical relevance with deep sequencing coverage over regions of interest.
Generates minimal non-target data, streamlining bioinformatic throughput.
Readily interpretable, making it the preferred approach for routine clinical diagnostic workflows.
Limitations:
Incapable of identifying pathogenic variants residing in genes absent from the pre-selected panel.
Clinically uninformative when an affected individual's condition is driven by an uncharacterized or atypical causative gene.
Strategic standing: current frontline modality for routine clinical molecular diagnostics.
Direct Comparison Matrix:
Target coverage:
WGS: entire genome (coding and non-coding regions).
WES: protein-coding regions only ( of genome).
Targeted panel: selected gene subsets associated with specific diseases.
Relative volume of generated data:
WGS: highest.
WES: intermediate.
Targeted panel: lowest.
Non-coding region representation:
WGS: fully included.
WES: mostly excluded.
Targeted panel: usually excluded.
Primary operational advantage:
WGS: broadest investigative capability across all genomic loci.
WES: highly efficient interrogation of the clinically dense coding space.
Targeted panel: deep, focused clinical evaluation with minimal extraneous data.
Primary operational limitation:
WGS: complex variant interpretation and massive data management demands.
WES: fails to capture pathogenic non-coding and deep-intronic variants.
Targeted panel: strictly limited to pre-selected genes; cannot discover novel causes.
Practical implementation context:
WGS: expanding future frontier of genomic medicine.
WES: research discovery engine and secondary clinical diagnostic.
Targeted panel: daily frontline standard in routine diagnostics.
Sanger Sequencing Versus Next Generation Sequencing
Sanger Sequencing fundamentals:
Relies on the selective incorporation of chain-terminating dideoxynucleotide triphosphates (ddNTPs) during in vitro DNA replication.
Operates as a two-stage sequential workflow requiring separate amplification (e.g., standard PCR) followed by the capillary electrophoresis sequencing reaction.
Next Generation Sequencing fundamentals:
Built upon the concept of sequencing by synthesis, in which nucleotide base incorporation is monitored in real-time as the complementary strand is constructed.
Massively parallel design permits millions of independent, compartmentalized sequencing reactions to occur synchronously.
Parametric Comparison:
Sequencing capacity:
Sanger: typically restricted to a single target DNA amplicon per reaction vessel.
NGS: millions of distinct DNA fragments interrogated simultaneously.
Core biochemical principle:
Sanger: dideoxy chain termination.
NGS: sequencing by synthesis.
Data throughput:
Sanger: low.
NGS: exceptionally high.
Large-scale applicability:
Sanger: highly inefficient and cost-prohibitive for large genomic regions.
NGS: ideally suited for multi-gene, exome, and whole-genome profiling.
Clinical diagnostic role:
Sanger: targeted single-gene testing and orthogonal confirmation of NGS-identified variants.
NGS: primary broad-scale genetic discovery, variant screening, and panel diagnostics.
Cost per sequenced base:
Sanger: relatively high.
NGS: exceptionally low.
The 11-Step NGS Technical Workflow (Ion Proton Platform)
Step 1: DNA Quality Control (QC):
DNA integrity and absolute concentration must be verified before downstream processing; fragmented or degraded starting material impairs library quality and downstream variant calling.
Assessed via agarose gel electrophoresis using an explicit DNA integrity scoring scale:
Score : No discernible DNA present or complete absence of high-molecular-weight DNA.
Score : Extensive degraded smearing throughout the high-molecular-weight region.
Score : Distinct high-molecular-weight band accompanied by substantial degraded smearing.
Score : Robust high-molecular-weight band showing only limited, minor smearing.
Score : High-integrity high-molecular-weight band with negligible or no smearing.
Operational impact: samples demonstrating higher scores () yield reliable, high-fidelity sequencing libraries; degraded samples risk severe allelic drop-out and low sequencing fidelity.
Step 2: DNA Fragmentation:
High-molecular-weight genomic DNA is physically or enzymatically sheared into uniform, short fragments approximately in length.
Biophysical requirement: current high-throughput sequencing instruments cannot process continuous, intact chromosomes; breaking molecules into calibrated units permits successful fluidic handling, target capture, and clonal amplification.
Step 3: End Repair and Denaturation:
Shearing generates uneven, jagged termini termed sticky ends that cannot accept downstream adapter sequences.
End repair enzymatically polishes fragment termini via exonuclease/polymerase treatment to generate blunt, 5'-phosphorylated ends.
Following repair, double-stranded DNA (dsDNA) is thermally or chemically denatured into single-stranded DNA (ssDNA).
Biological requirement for denaturation: strand separation is mandatory to expose nucleotide sequences, enabling sequence-specific complementary capture probes to hybridize during target enrichment.
Step 4: Target Enrichment (Hybridisation Capture):
Selectively enriches specific target loci (such as all coding exons or a clinical gene panel) out of the broader genomic pool.
Bait/Probe architecture:
Probes are synthetic oligonucleotides engineered to be the exact reverse complement of target genomic regions.
Design example: a target genomic sequence of is captured using an engineered reverse-complementary probe of .
Detailed biochemical mechanism of hybridisation capture:
Biotinylated DNA probes: sequence-specific capture probes are functionalized with a covalent biotin tag.
Hybridisation: biotin-labeled probes are incubated with denatured ssDNA libraries, selectively annealing to complementary genomic targets.
Streptavidin-coated magnetic beads: paramagnetic beads coated with streptavidin are introduced, forming high-affinity non-covalent streptavidin-biotin complexes.
Magnetic rack immobilization: the reaction vessel is mounted on a magnetic rack; the magnetic field sequesters the bead-probe-target complexes against the tube wall.
Washing and target elution: non-hybridized, off-target genomic DNA is washed away; captured target fragments are chemically eluted and recovered.
Step 5: Adapter Ligation and Bead Preparation:
Specialized synthetic oligonucleotide adapters are ligated to both ends of the enriched DNA fragments.
Adapter functional properties:
Provide anchor sequences that anneal to complementary oligonucleotides bound to the surface of sequencing beads.
Carry sequencing primer binding sites.
Barcoding and multiplexing:
Barcodes consist of unique, short index nucleotide sequences embedded within the adapters.
Barcodes tag all fragments derived from a specific patient, permitting dozens of distinct biological samples to be pooled and sequenced within the same physical instrument run (multiplexing), followed by in silico bioinformatic de-multiplexing.
Stoichiometric binding to sequencing beads:
Parametric control is calibrated to achieve a precise stoichiometric ratio of approximately .
Critical necessity: limiting dilution ensures that each bead hosts only one unique biological template molecule, preventing mixed polyclonal sequence signals during downstream synthesis.
Step 6: Clonal Amplification via Emulsion PCR (emPCR):
Technical basis: a water-in-oil emulsion creates billions of discrete, microscopic aqueous micro-droplets suspended in oil.
Droplet functionality: each individual water droplet behaves as an isolated, self-contained PCR micro-reactor containing a single bead, a single target DNA template, DNA polymerase, dNTPs, and primers.
Reaction mechanism:
DNA fragments bind sequencing beads.
Beads are partitioned into oil-emulsion micro-reactors.
Thermal cycling drives localized PCR amplification of the single template.
By reaction completion, each individual bead is densely coated with millions of immobilized, identical copies of the initial DNA fragment.
DNA is rendered single-stranded at the completion of emPCR.
Purpose: single-molecule nucleotide incorporations emit signals below the physical detection thresholds of the sequencing sensor; clonal amplification magnifies the signal to ensure reliable detection.
Step 7: Sequencing by Synthesis on Semiconductor Chips:
Chip loading: clonally amplified, ssDNA-coated beads are deposited via gravity into microscopic reaction wells on an Ion Proton semiconductor sequencing chip, with each well isolating an individual bead.
Sequential dNTP delivery:
Unlabeled dNTP species (dATP, dCTP, dGTP, dTTP) are sequentially washed across the chip one at a time in predetermined cycles, unlike conventional PCR where all dNTPs are simultaneously present.
If the flowed nucleotide is complementary to the template base immediately adjacent to the primer, DNA polymerase incorporates it into the nascent strand.
Ion Proton detection physics:
Biochemical event: the enzymatic formation of a covalent phosphodiester bond releases a pyrophosphate molecule and a single hydrogen ion ().
Biophysical readout: the generation of free alters the localized pH within the micro-well ().
Semiconductor sensor: an ion-sensitive field-effect transistor (ISFET) sensor underlying each well measures the pH shift and translates it into a digital voltage change, directly identifying the incorporated base.
Homopolymer sequencing error liability:
Homopolymers are uninterrupted stretches of identical consecutive bases (e.g., AAAA or GGGG).
During a complementary nucleotide flow, multiple identical bases are incorporated simultaneously, releasing a proportional, cumulative burst of ions.
Sensor limitation: while a single base incorporation yields a baseline signal and two bases yield double the voltage, the semiconductor sensor struggles to reliably distinguish subtle voltage differences between higher order repeats (e.g., differentiating vs identical bases).
System limitation: homopolymer-associated insertion/deletion (indel) miscalls represent the primary technical error profile of the Ion Proton platform.
Step 8: Sequence Alignment:
Raw data generation: base-calling software converts voltage fluctuations into millions of discrete short nucleotide strings termed reads.
Read definition: the determined linear sequence of nucleotides originating from an individual DNA fragment.
Alignment process: computationally matching and mapping these millions of short reads back to their unique homologous coordinates along an established linear human reference genome.
Structural utility: aligns overlapping read stacks against the reference locus, allowing algorithms to observe true genomic deviations (such as heterozygous single base changes) supported across multiple independent reads.
Step 9: Variant Calling and Zygosity Estimation:
Variant calling: the bioinformatic process of differentiating true biological departures from the reference genome versus background machine noise, outputting all verified deviations into a standardized Variant Call Format (VCF) file.
Zygosity definitions:
Homozygous reference: both inherited maternal and paternal alleles precisely match the reference genome sequence.
Heterozygous: one inherited allele matches the reference sequence while the alternative allele harbors a variant sequence.
Homozygous variant: both inherited alleles harbor the identical non-reference variant sequence.
Variant allele read proportion criteria:
Variant read proportion : classified as Homozygous reference (deviations discounted as sequencing noise or technical artifact).
Variant read proportion : classified as Heterozygous (representing roughly balanced expression of reference and variant alleles).
Variant read proportion : classified as Homozygous variant (representing nearly pure alternative allele capture).
Mathematical calculation of variant frequency:
Calculated as: .
Diagnostic example: if a locus possesses a depth of reads, and of those reads carry a single nucleotide substitution, the calculated variant proportion is:
Classification: according to clinical guidelines, falls within the window, designating the variant as Heterozygous.
Step 10: Variant Annotation:
The programmatic integration of rich biological, evolutionary, and clinical metadata into raw VCF coordinates to facilitate functional impact prediction.
Essential annotation fields:
Gene name: identifies the affected canonical locus.
Chromosomal position: records the specific base coordinate.
Structural locus: categorizes whether the change is exonic, intronic, or splice-site.
Variant type: defines the mutation class.
Transcript ID: designates the specific reference RNA isoform.
Amino acid change: records the predicted alteration to the protein primary structure.
Read counts: details the raw coverage depth supporting reference and variant alleles.
Structural variant classifications:
Synonymous: nucleotide substitution that does not alter the encoded amino acid due to genetic code degeneracy.
Missense: nucleotide substitution resulting in a codon that translates to a chemically distinct amino acid.
Frameshift: insertion or deletion of nucleotides in numbers not divisible by three, disrupting the downstream triplet reading frame and generating truncated non-functional proteins.
Insertion: the addition of one or more base pairs into the genomic sequence.
Deletion: the excision of one or more base pairs from the genomic sequence.
Splice-related: mutations falling within canonical splice-donor or splice-acceptor dinucleotides, predisposing to improper intron retention or exon skipping during mRNA splicing.
Functional significance: raw nucleotide coordinates cannot inform pathogenicity; annotation is required to determine whether an identified mutation damages protein function.
Step 11: Variant Filtering and Prioritisation:
Rationalization: a typical exome run yields tens of thousands of variants, the vast majority being benign polymorphisms; manual curation of every variant is impossible.
Filtering logic in rare Mendelian disease:
Population frequency filtering: variants common in general population databases are excluded, as highly prevalent variants cannot explain rare, highly penetrant clinical phenotypes.
Gene-disease association: prioritizes genes previously implicated in relevant physiological systems or matches with human phenotype ontology.
Predicted functional consequence: prioritizes loss-of-function variants (frameshifts, stop gains, splice disruptions) and deleterious missense variants over neutral changes.
Inheritance pattern consistency: filters variants based on expected Mendelian models (autosomal dominant, autosomal recessive, X-linked).
Clinical phenotype correlation: cross-references candidate genes with the specific clinical presentation of the patient.
Summary of the 11-Step NGS Technical Pipeline
Step 1 (Quality Control): evaluates starting DNA quantity and molecular integrity via electrophoretic scoring to eliminate degraded inputs.
Step 2 (Fragmentation): enzymatically or mechanically shears genomic DNA into uniform, manageable units approximately long.
Step 3 (End Repair): repairs uneven sticky ends into blunt, phosphorylated ends and denatures double-stranded DNA into single-stranded templates.
Step 4 (Target Enrichment): isolates regions of interest via hybridisation capture using biotinylated complementary probes, streptavidin beads, and magnetic racks.
Step 5 (Adapter Addition and Bead Preparation): ligates universal sequencing adapters and sample-specific multiplexing barcodes, annealing DNA to beads at a ratio of approximately .
Step 6 (Clonal Amplification): executes emulsion PCR within isolated water-in-oil micro-droplets to coat beads with millions of uniform single-stranded copies of a single template.
Step 7 (Sequencing by Synthesis): microfluidically delivers sequential dNTP flows across an Ion Proton chip, detecting nucleotide incorporation via ISFET sensor measurement of ion release and pH shifts.
Step 8 (Sequence Alignment): maps millions of determined short sequencing reads back to homologous coordinates on a human reference genome.
Step 9 (Variant Calling): identifies biological differences between aligned reads and the reference, determining zygosity thresholds and outputting data to a VCF file.
Step 10 (Variant Annotation): attaches functional, structural, and biochemical metadata to all cataloged variants.
Step 11 (Variant Filtering): systematically enriches for high-priority pathogenic candidate mutations by applying population frequency, functional severity, and phenotypic filters.
Technical Limitations and Variant Interpretation Challenges
Intrinsic technical limitations of high-throughput sequencing:
Sequencing artefacts: in vitro polymerase errors, library preparation damage, or optical/semiconductor sensor noise can mimic genuine mutations, producing false-positive calls.
Incorrect zygosity calling: low sequence read depth, allelic drop-out during amplification, or mapping errors can cause an analytical pipeline to misclassify a heterozygous locus as homozygous or vice versa.
Difficult genomic architectures:
GC-rich regions: DNA sequences with high guanine and cytosine content resist denaturation and amplification, causing extreme coverage bias or regional drop-out.
Repetitive sequences: short tandem repeats, homopolymers, and segmental duplications cannot be mapped back to a unique reference coordinate with short reads, leaving these regions unresolvable.
Sanger sequencing confirmation: diagnostic protocol mandates that NGS-identified candidate mutations undergo independent validation using conventional Sanger sequencing before issuing definitive clinical reports.
Genetic and biological barriers to variant interpretation:
Synonymous variants: because they alter no amino acids, their downstream impacts on cryptic splice junctions, translation kinetics, or mRNA secondary structure are difficult to predict in silico.
Intronic and non-canonical splicing variants: changes outside classical splice sites frequently alter intronic splicing enhancers or silencers, but validating these disruptions requires functional RNA analysis.
Missense variants within large genes: large structural proteins (e.g., titin, dystrophin) naturally accrue hundreds of benign missense variations, making the isolation of the single pathogenic mutation exceptionally difficult.
Multi-gene convergent pathways: identical clinical disease features regularly arise from independent lesions scattered across dozens of different genes acting within a common biological pathway.
Variable penetrance and genetic modifiers: the presence of an established pathogenic variant does not guarantee uniform clinical disease; penetrance describes the proportion of individuals carrying a genotype that express the phenotype. Incomplete penetrance and epistatic modifier genes can cause identical variants to present as devastating disease in an index case while remaining completely asymptomatic in a carrier parent.
Obscure gene mechanisms: many high-confidence variants fall within poorly characterized genes that lack established biochemical functions or disease animal models, precluding definitive clinical assignment.
The "needle among many needles" paradigm: an individual genome contains millions of benign variants; finding a sequence variation is not equivalent to establishing causality, requiring rigorous clinical and functional validation.
Clinical Utility and Impact of Genomic Diagnostics
Immediate diagnostic and therapeutic outcomes:
Unambiguously establishes the underlying molecular etiology for a complex constellation of symptoms.
Directly dictates clinical management strategies (e.g., selecting gene-directed pharmacotherapies, avoiding contraindicated interventions).
Provides precise prognostic guidance regarding disease trajectory, anticipated complications, and life expectancy.
Familial and systemic healthcare advantages:
Empowers accurate genetic counseling regarding recurrence risks for family members.
Informs pre-implantation genetic diagnosis, prenatal screening, and targeted reproductive planning.
Spares vulnerable patients from undergoing repeated invasive diagnostic investigations, such as nerve and muscle biopsies or serial electromyography.
Elucidates fundamental human biology and disease pathophysiology, identifying novel molecular targets for downstream therapeutic development.
Glossary of Key Genomic Terminology
Next Generation Sequencing (NGS): a high-throughput molecular methodology enabling the simultaneous parallel sequencing of millions of independent DNA fragments.
Monogenic disease: an inherited clinical disorder caused by a pathogenic mutation residing within a single defined gene.
Whole Genome Sequencing (WGS): a comprehensive sequencing strategy interrogating the entire continuous sequence of an organism's genome, including coding and non-coding loci.
Whole Exome Sequencing (WES): a targeted sequencing strategy that selectively enriches and analyzes only the protein-coding exons ( of the human genome).
Targeted Gene Panel: a diagnostic sequencing strategy dedicated exclusively to a pre-defined subset of genes associated with a specific clinical phenotype.
Read: a short continuous stretch of nucleotide sequence generated by a sequencing platform from a single biological fragment of DNA.
Bait / Probe: a synthetic single-stranded oligonucleotide engineered to be the reverse complement of a specific genomic sequence, used to isolate target sequences via hybridization.
Hybridisation: the specific hydrogen bonding and annealing of two single-stranded nucleic acid molecules via complementary base pairing.
Biotin: a small, stable vitamin co-factor attached to molecular probes to serve as a high-affinity capture tag.
Streptavidin: a bacterial tetrameric protein that forms one of the strongest non-covalent biological bonds known with biotin, utilized on magnetic beads for target enrichment.
Adapter: a defined, synthetic double-stranded or single-stranded oligonucleotide ligated to the ends of DNA fragments to mediate bead binding, amplification, and instrument sequencing.
Barcode: a distinct, sequence-defined oligonucleotide index incorporated into adapters to uniquely label distinct biological samples.
Multiplexing: the practice of pooling multiple distinct barcoded DNA libraries into a single sequencing run, followed by bioinformatic demultiplexing based on barcode sequences.
Clonal amplification: the localized generation of millions of identical copies from a single parent DNA molecule to elevate signal intensity above detection thresholds.
Emulsion PCR (emPCR): an in vitro clonal amplification technique that isolates individual beads and single template molecules inside water-in-oil micro-droplets functioning as independent PCR micro-reactors.
Sequence Alignment: the computational process of mapping individual short reads to their unique homologous coordinates within a standardized linear reference genome.
Variant calling: the bioinformatic process of identifying, filtering, and scoring true nucleotide sequence differences between mapped reads and a reference genome.
Variant Call Format (VCF): the standardized bioinformatic text file format used to record identified genomic variations, genotypes, read depths, and associated quality metrics.
Variant Annotation: the computational addition of genomic, functional, transcriptional, and clinical metadata to individual variants documented within a VCF file.
Variant Filtering: the systematic bioinformatic reduction of massive variant datasets by excluding common polymorphisms and non-pathogenic variants to enrich for candidate disease-causing mutations.
Zygosity: the allelic state of a specific genetic locus, defining whether the maternal and paternal alleles possess identical sequences (homozygous) or discordant sequences (heterozygous).